The CJC 1295 DAC GHRH analog is a synthetic tetrasubstituted peptide modified with a Drug Affinity Complex to extend circulating stability in preclinical research. Designed to target pituitary growth-hormone-releasing hormone receptors, it serves as a critical model for investigating sustained somatotropic stimulation and downstream IGF-1 transcription. PX1 Research supplies high-purity, USA-manufactured CJC-1295 DAC strictly for laboratory and in vitro applications.
The CJC 1295 DAC GHRH analog is a synthetic tetrasubstituted peptide modified with a Drug Affinity Complex to extend circulating stability in preclinical research. Designed to target pituitary growth-hormone-releasing hormone receptors, it serves as a critical model for investigating sustained somatotropic stimulation and downstream IGF-1 transcription. PX1 Research supplies high-purity, USA-manufactured CJC-1295 DAC strictly for laboratory and in vitro applications.
The **cjc 1295 dac ghrh analog** is a synthetic 29-amino-acid peptide derived from the native sequence of human growth-hormone-releasing hormone (GHRH 1-29). It incorporates four amino acid substitutions—specifically D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27—designed to enhance enzymatic resistance against dipeptidyl peptidase IV (DPP-IV). The defining molecular modification of this derivative is the addition of a maleimidopropionic acid linker, commercially designated as the Drug Affinity Complex (DAC), attached to the C-terminal lysine residue.
In preclinical settings, the native GHRH peptide exhibits a rapid elimination half-life of less than twelve minutes due to aggressive cleavage by plasma proteases. By conjugating the reactive maleimide group of the DAC entity to the free thiol group of cysteine-34 on circulating serum albumin, the CJC-1295 DAC research compound forms a stable, covalent bioconjugate. This chemical coupling preserves GHRH receptor affinity while protecting the peptide core from renal filtration and enzymatic degradation, establishing a extended functional duration in laboratory models.
The primary biochemical distinction of the CJC 1295 DAC GHRH analog lies in its reactive bioconjugation chemistry. When introduced to biological matrices containing albumin, the maleimide motif undergoes a specific nucleophilic addition reaction with the unpaired Cys34 residue of endogenous albumin. This reaction occurs rapidly under physiological pH conditions, yielding a stable thiosuccinimide linkage that anchors the peptide to the long-lived plasma carrier.
Preclinical pharmacokinetic evaluations in rodent models demonstrate that non-conjugated GHRH analogs exhibit rapid plasma clearance, requiring frequent experimental administration to maintain receptor occupancy. Conversely, the bioconjugated CJC 1295 DAC complex remains in circulation for extended periods, displaying a half-life of several days in murine models. Researchers utilizing the PX1 Research peptide library analyze this structural adaptation to observe how continuous GHRH receptor stimulation alters baseline pituitary gene expression compared to pulsatile administration vectors.
In vitro and animal model studies indicate that the CJC 1295 DAC GHRH analog selective binds to the GHRH receptor (GHRHR) located on anterior pituitary somatotropes. Activation of GHRHR initiates a G-protein-coupled signal transduction cascade, stimulating adenylate cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP). This signaling pathway promotes the transcription and exocytosis of endogenous growth hormone (GH).
Unlike short-acting secretagogues that induce transient GH spikes, preclinical literature confirms that CJC-1295 DAC maintains elevated basal levels of GH and downstream insulin-like growth factor 1 (IGF-1) without disrupting the physiological feedback loops entirely. In rodent tissue repair models, sustained elevation of circulating IGF-1 has been correlated with heightened nitrogen retention, accelerated cellular proliferation in damaged muscular tissue, and enhanced extracellular matrix deposition. These findings make the compound a staple in laboratory research investigating skeletal muscle regeneration and metabolic rate regulation.
When designing protocols for somatotropic axis investigation, researchers frequently evaluate the structural and kinetic differences between GHRH analogs and growth hormone secretagogue receptor (GHSR) agonists. The inclusion of the Drug Affinity Complex fundamentally alters the experimental parameters, shifting the compound from a short-acting pulse inducer to a long-acting background agonist.
A clear contrast exists between long-acting and short-acting compounds within the same chemical class. For instance, Mod GRF 1-29 (CJC-1295 without DAC) retains the same four amino acid substitutions for DPP-IV resistance but lacks the maleimide linker, resulting in a brief circulating half-life (~30 minutes) ideal for mimicking natural GH pulses. Conversely, Ipamorelin acts via the ghrelin receptor pathway rather than the GHRH receptor, generating selective GH release without elevating cortisol or prolactin. Researchers often contrast these mechanisms against Sermorelin, an unmodified GHRH 1-29 derivative, when analyzing receptor desensitization kinetics. Detailed comparative breakdowns are available in our guide on GHRP vs GHRH analog kinetics.
Proper reconstitution technique is essential to maintain the structural integrity of the CJC 1295 DAC GHRH analog and preserve the reactivity of its maleimide linker. Lyophilized peptide cakes should be reconstituted using sterile, laboratory-grade bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline, depending on the requirements of the downstream assay.
To solubilize the sample, introduce the diluent slowly along the glass wall of the vial to minimize shear force and bubble formation. Gentle swirling is recommended; aggressive agitation or vortexing can cause mechanical denaturation or aggregation of the peptide chain. Once solubilized, calculations for micro-molar concentration should account for total vial mass (e.g., 2 mg or 5 mg) verified by analytical lot documentation. Laboratory accounts requiring bulk quantities for high-throughput screening can explore custom batch options via the PX1 wholesale program.
Lyophilized CJC-1295 DAC maintains chemical stability when stored in a climate-controlled environment away from direct light. For short-term transit, the dry powder remains stable at ambient temperatures; however, long-term storage in laboratory archives requires temperature management at -20°C or -80°C to prevent slow hydrolytic degradation.
Following reconstitution, liquid aliquots are prone to gradual degradation through peptide bond hydrolysis and potential degradation of the reactive maleimide ring if exposed to elevated temperatures or alkaline pH. Reconstituted solutions should be stored at 2°C to 8°C and utilized within 21 to 28 days. Avoid repeated freeze-thaw cycles, as micro-ice crystal formation induces physical shear that alters peptide tertiary structure. Researchers studying related compounds like GHRP-2 and GHRP-6 variants must follow identical thermal management standards.
Because structural impurities and truncated peptide fragments can invalidate receptor binding assays, research facilities must insist on absolute analytical transparency. High-performance liquid chromatography (RP-HPLC) and electrospray ionization mass spectrometry (ESI-MS) represent the gold standard for verifying chemical identity and purity of the CJC 1295 DAC GHRH analog.
PX1 Research enforces rigorous quality control protocols for every lot synthesized. Our compounds are subjected to third-party testing in ISO 17025 accredited analytical facilities, confirming total peptide purity of ≥98% via RP-HPLC and verifying exact molecular mass via ESI-MS. Furthermore, because bacterial contamination can alter cell culture behavior, all lots undergo kinetic chromogenic LAL assays to ensure endotoxin levels remain strictly below <0.01 EU/mg, protecting the validity of sensitive in vitro and preclinical models.
Obtaining reliable data in somatotropic axis research requires peptides synthesized under standardized conditions with full batch traceability. Substandard compounds containing unreacted maleimide precursor, residual synthesis solvents, or ambiguous peptide content introduce confounding variables that compromise scientific reproducibility.
PX1 Research manufactures all research compounds inside state-of-the-art, GMP-compliant facilities within the USA. Each shipment includes a lot-specific Certificate of Analysis (COA) detailing raw HPLC chromatograms and mass spectral data. Orders are fulfilled directly from our primary distribution hubs in California and Arizona, offering same-day dispatch for orders placed Monday through Friday. Explore our complete line of verified materials in the PX1 product catalog to support your ongoing laboratory protocols.
What is the primary mechanism of the CJC 1295 DAC GHRH analog?
The CJC 1295 DAC GHRH analog acts as a selective growth-hormone-releasing hormone receptor (GHRHR) agonist. Its Drug Affinity Complex (DAC) permits covalent binding to circulating serum albumin, extending its biological half-life and maintaining sustained GHRH signaling in preclinical research models.
How does CJC-1295 with DAC differ structurally from Mod GRF 1-29?
Both peptides feature the same four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) to resist DPP-IV enzymatic cleavage. However, CJC-1295 DAC includes a maleimidopropionic acid linker at the C-terminus, enabling covalent attachment to albumin, whereas Mod GRF 1-29 lacks this linker and exhibits a much shorter circulating half-life.
What purity levels are guaranteed for PX1 Research CJC-1295 DAC?
PX1 Research guarantees a minimum chemical purity of ≥98% for every lot of CJC-1295 DAC, as verified by reverse-phase high-performance liquid chromatography (RP-HPLC) and electrospray ionization mass spectrometry (ESI-MS).
What are the acceptable endotoxin limits for laboratory cell culture research?
For sensitive cell culture and in vitro biochemical assays, endotoxin levels should remain below 0.05 EU/mg. PX1 Research tests every batch to ensure endotoxin levels measure strictly under <0.01 EU/mg.
How should lyophilized CJC-1295 DAC be stored upon arrival?
Lyophilized CJC-1295 DAC should be stored in a freezer at -20°C for long-term preservation. For short-term storage prior to reconstitution, keeping the vial desiccated at 2°C to 8°C protected from direct light is sufficient.
Which diluent is recommended for reconstituting CJC-1295 DAC for lab use?
Reconstitution is typically performed using laboratory-grade sterile bacteriostatic water (containing 0.9% benzyl alcohol) or sterile 0.9% saline, depending on the specific buffer requirements of the planned assay.
What preclinical outcomes are associated with CJC-1295 DAC exposure in rodent models?
Preclinical rodent studies document sustained elevations in serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1), leading to research observations focused on cellular repair, protein synthesis, and nitrogen balance.
Where are PX1 Research compounds manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and shipped directly from our primary fulfillment centers located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.